KRAS and pancreatic neoplasm: We examined the dose-dependent effects of KRAS-targeting PPRHs (144 h) on the viability of KRAS mutant expression pancreatic cancer cell lines AsPc-1 (G12D, highly addicted to KRAS) and MiaPaCa-2 (G12C, moderately addicted to KRAS) and KRAS overexpressing ovarian cancer SKOV-3 cell lines (Figure 4A).